Here is a link to an article that ran in The Seattle Times on Thursday under the headline "ZymoGenetics on track for final testing of key drug, Thrombin." You may need to register to view it since it's now in the archives, but it's free if you do. http://tinyurl.com/6w7blSome snippets are below...Encouraged by earlier tests of a treatment for surgical bleeding, ZymoGenetics plans for the first time to take one of its drugs into the final phase of clinical testing. The genetically engineered product, Thrombin, is important to ZymoGenetics strategically because it represents the company's initial attempt to develop on its own a product that could gain FDA approval. Before spinning off as an independent public company in 2000, ZymoGenetics discovered several drugs now on the market, but those were taken through clinical trials at other companies......ZymoGenetics isn't forecasting the market potential yet for its human version of Thrombin, but it said the cow-derived competitor is expected to reach $165 million in sales this year. Williams said Thrombin could conceivably be used for up to half a million surgeries a year in America, even though the cow-derived product isn't used that widely. He said ZymoGenetics' product will likely be priced at a premium over the cow-derived version, which commonly sells for $150 per surgery. MESuther13
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra